4 JUL 2024

Statement Chemometec Ahead of AGM

Following a total of eight changes in senior management (CEO and CFO) positions at ChemoMetec in the last five years, our assessment is that there is a need for structural quality improvement in the governance of the company.

ChemoMetec has built a strong global niche position in high quality analytical equipment for cell counting over many years. Its products and consumables generate productivity gains in critical research areas such as cell-based therapy, cancer and stem cell research. It does so profitably and is generating a handsome cash flow for its shareholders, with a solid balance sheet with over 300 DKKm net cash.

However, in order to achieve a continued long term success, we believe the company needs to take steps to improve how it communicates with the market and make reforms in its corporate governance policies. In a recent research note from SEB, comparing ChemoMetec with Danish peers within health and medical technology, the company unfortunately stands out in terms of non- or only partly compliance with Danish recommendations on corporate governance. Despite taking concrete positive steps to improve over recent years, ChemoMetec is still noncompliant or only partly compliant on 11 of 40 recommendations, compared to only three at the next worse peer.

All structural, durable improvement starts at the top. To ensure that the board is elected in a professional manner, we propose that the company institute a nomination committee at its annual general meeting on October 10. As mentioned, there are several steps that the company could and should take to improve corporate governance. We would view the institution of a nomination committee for selecting board members as a particularly positive step in the direction of quality and maturity of the company.

Denmark is, like its Scandinavian cousins, an open economy, which is a policy that we think has served our nations well. ChemoMetec is an excellent example of success within the Danish cluster in health and medical technology. As all such clusters it is worth defending, preserving and growing. Every step on the journey toward quality and maturity the company can take improves its chances to act from a position of strength in the future.

Carl Armfelt
Erik Sprinchorn


Historisk avkastning är inte någon garanti för framtida avkastning. De pengar du investerar i fonder kan både öka och minska i värde och det är inte säkert att du får tillbaka hela det insatta kapitalet. Faktablad, informationsbroschyrer och fondbestämmelser för våra fonder finns att hämta på vår hemsida eller hos någon av våra återförsäljare.
Edit cookie settings